Apixaban vs Edoxaban
## Overview
Apixaban and edoxaban are both factor Xa inhibitors with once-daily (edoxaban) or twice-daily (apixaban) dosing. Apixaban generally has the best-tolerated bleeding profile in meta-analyses; edoxaban has the unique restriction of reduced efficacy at CrCl >95 mL/min.
## Pharmacokinetics
Apixaban: ~50% bioavailability, ~27% renal clearance, twice daily. Edoxaban: ~62% bioavailability, ~50% renal clearance, once daily. Edoxaban's higher renal dependence means greater dose reduction in moderate-to-severe CKD.
## Clinical Evidence
ARISTOTLE (apixaban): superior to warfarin for AF — statistically better efficacy AND bleeding. ENGAGE AF-TIMI 48 (edoxaban): non-inferior to warfarin with less major bleeding. Network meta-analyses consistently show apixaban with the most favorable efficacy-safety balance.
## Key Considerations
Edoxaban is unique in that high renal clearance (CrCl >95 mL/min) reduces its plasma concentration to levels that may be insufficient for stroke prevention — this is a key FDA boxed warning. Apixaban does not have this restriction.
## Key Takeaways
- Apixaban: twice-daily, lowest bleeding risk among DOACs, broader renal use
- Edoxaban: once-daily convenience, but avoid if CrCl >95 mL/min
- Apixaban generally preferred based on evidence synthesis
Verdict
Apixaban is generally preferred over edoxaban based on its superior evidence base (ARISTOTLE superiority to warfarin in both efficacy and safety) and absence of a high-CrCl restriction. Edoxaban once-daily dosing may improve adherence in some patients.